Sera Prognostics (Sera Prognostics) ROCE % : -42.92% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sera Prognostics's annualized ROCE % for the quarter that ended in Dec. 2023 was -42.92%.

Sera Prognostics ROCE % Historical Data

The historical data trend for Sera Prognostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics ROCE % Chart

Sera Prognostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-83.83

-172.26

-48.20

-36.86

-42.13

Sera Prognostics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial												-37.29	-43.82	-48.32	-36.20	-42.92

Sera Prognostics ROCE % Calculation

Sera Prognostics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.187	/	( ( (116.329 - 15.538)	+	(95.441 - 24.443) )	/ 2 )
	=	-36.187	/	( (100.791	+	70.998)	/ 2 )
	=	-36.187	/	85.8945
	=	-42.13 %

Sera Prognostics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-31.656	/	( ( (90.057 - 13.545)	+	(95.441 - 24.443) )	/ 2 )
	=	-31.656	/	( ( 76.512	+	70.998 )	/ 2 )
	=	-31.656	/	73.755
	=	-42.92 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Sera Prognostics (NAS:SERA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sera Prognostics ROCE % Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sera Prognostics (Sera Prognostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109

Website

https://www.seraprognostics.com

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.

Executives

John J. Boniface	officer: Chief Scientific Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson	officer: General Counsel	320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts	officer: Chief Financial Officer	2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison	officer: Chief Information Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley	officer: Chief Medical Officer	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence	director	C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt	director	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney	officer: Chief Data Officer	2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc	10 percent owner	239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin	officer: VP OF Q/R & HIPPA PRIV. OFF	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare	officer: Chief Commercial Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109